Edition:
United Kingdom

Egalet Corp (EGLT.OQ)

EGLT.OQ on NASDAQ Stock Exchange Global Market

0.96USD
19 Jan 2018
Change (% chg)

$0.05 (+5.93%)
Prev Close
$0.91
Open
$0.89
Day's High
$0.97
Day's Low
$0.89
Volume
104,764
Avg. Vol
245,239
52-wk High
$5.58
52-wk Low
$0.80

Latest Key Developments (Source: Significant Developments)

Broadfin Capital Reports 9.99 Pct Passive Stake In Egalet Corp
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Egalet Corp ::BROADFIN CAPITAL LLC REPORTS A 9.99 PCT PASSIVE STAKE IN EGALET CORP AS OF DEC 27, 2017 - SEC FILING.  Full Article

Egalet Partners With Orapharma To Co-Promote Sprix Nasal Spray
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Egalet Corp ::EGALET PARTNERS WITH ORAPHARMA TO CO-PROMOTE SPRIX® NASAL SPRAY.EGALET CORP - FINANCIAL TERMS OF AGREEMENT WILL NOT BE DISCLOSED.EGALET CORP - ‍ORAPHARMA WILL BEGIN PROMOTING SPRIX IN Q1 AS PART OF A TWO-YEAR AGREEMENT​.EGALET CORP - HAS TERMINATED ITS AGREEMENT WITH SEPTODONT.  Full Article

Egalet Reduces Announces Refinancing Of Existing Convertible Notes
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Egalet Corp ::EGALET REDUCES DEBT OBLIGATION, EXTENDS MATURITY AND LOWERS ANNUAL INTEREST PAYMENTS THROUGH REFINANCING OF EXISTING CONVERTIBLE NOTES.EGALET CORP - ‍ENTERED INTO EXCHANGE AGREEMENTS WITH CERTAIN HOLDERS OF EGALET'S OUTSTANDING 5.50% SENIOR CONVERTIBLE NOTES DUE APRIL 1, 2020​.EGALET CORP - ‍TOTAL FACE VALUE OF COMPANY'S CONVERTIBLE DEBT WILL BE REDUCED FROM $61.0 MILLION TO $48.5 MILLION THROUGH EXCHANGE​.EGALET - TOTAL PRINCIPAL AMOUNT OUTSTANDING OF EXISTING NOTES TO BE REDUCED, MATURITY DATE OF NEW NOTES IS DEC 2024-A 5-YEAR EXTENSION FROM ORIGINAL DATE.  Full Article

Egalet Receives FDA Tentative Approval For Chronic Pain Treatment Drug
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Egalet Corp ::EGALET RECEIVES FDA TENTATIVE APPROVAL FOR EXPANDED LABEL FOR ARYMO® ER (MORPHINE SULFATE) C-II, AN EXTENDED-RELEASE MORPHINE PRODUCT FORMULATED WITH ABUSE-DETERRENT PROPERTIES FOR TREATMENT OF CHRONIC PAIN.EGALET - FINAL APPROVAL EXPECTED TO BE GRANTED WHEN EXCLUSIVITY PERIOD EXPIRES ON OCT. 2, 2018.EGALET CORP - ‍INTRANASAL ABUSE-DETERRENT CLAIM TO BE ADDED TO ARYMO ER PRESCRIBING INFORMATION LABEL FOR ARYMO ER C-II​.  Full Article

Egalet Corp's Phase 3 Study Of Egalet-002 In Patients With Moderate-To-Severe Chronic Low Back Pain Meets Primary Endpoint​
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Egalet Corp ::EGALET ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY EVALUATING EFFICACY AND SAFETY OF EGALET-002 IN PATIENTS WITH MODERATE-TO-SEVERE CHRONIC LOW BACK PAIN.EGALET CORP - ‍EGALET-002 WAS GENERALLY WELL-TOLERATED AND NO NEW SAFETY CONCERNS WERE IDENTIFIED IN STUDY​.EGALET CORP - ‍STUDY OF EGALET-002 MET ITS PRIMARY ENDPOINT​.  Full Article

Egalet Corp Says ‍Apotex Has Lost Right To Launch An Authorized Generic Version Of Sprix Nasal Spray​
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Egalet Corp ::EGALET CORP - ‍COMPANY DID NOT RECEIVE ANY WRITTEN NOTIFICATION ON OR BEFORE NOTIFICATION DEADLINE FOR PRODUCT LAUNCH FROM APOTEX CORP & APOTEX INC​.EGALET CORP - ‍APOTEX HAS LOST RIGHT TO LAUNCH AN AUTHORIZED GENERIC VERSION OF SPRIX NASAL SPRAY​.EGALET CORP - ‍IF APOTEX IS ABLE TO SATISFY REQUIREMENTS FOR LAUNCHING AN UNAUTHORIZED GENERIC, IT WOULD BE PERMITTED TO DO SO IN SEPTEMBER 2018​.  Full Article

Egalet notified that FDA will not meet PDUFA goal data for ARYMO ER
Thursday, 13 Oct 2016 

Egalet Corp : Egalet notified that FDA will not meet PDUFA goal data for ARYMO ER . Egalet Corp -FDA will not meet previously announced October 14 Prescription Drug User Fee Act (PDUFA) date for ARYMO ER . Egalet - FDA has identified no particular issue with Co's application for ARYMO ER and it is working on product label . On ARYMO ER - FDA indicated that they need more time as they have done with other abuse-deterrent opioid NDA .Egalet Corp - FDA confirms no additional scientific information or data is needed for application for ARYMO ER.  Full Article

Egalet reports Q2 loss per share $0.97
Thursday, 4 Aug 2016 

Egalet : Q2 loss per share $0.97 . Q2 earnings per share view $-0.82 -- Thomson Reuters I/B/E/S . Deterrent arymo(tm) er (morphine sulfate) and reports second quarter 2016 financial results . Q2 revenue $3.5 million versus i/b/e/s view $3.8 million . FDA prescription drug user fee act (pdufa) goal date for a decision is october 14, 2016. .Committees voted that if approved arymo er should be labeled as an abuse-deterrent product by intravenous, nasal and oral routes of abuse.  Full Article

Egalet announces issuance of two new U.S. patents for Guardian Technology
Tuesday, 19 Jul 2016 

Egalet Corp : U.S. Patent number 9,358,295 covers through 2031 immediate-release formulations intended to be resistant to abuse by intake of alcohol . U.S. Patent number 9,375,428 covers through 2024 extended-release formulations of opioids .Egalet announces issuance of two new U.S. Patents for Guardian™ Technology.  Full Article

Egalet says FDA advisory committee meeting on August 4 for ARYMO™
Tuesday, 28 Jun 2016 

Egalet Corp : Egalet announces FDA advisory committee meeting will take place August 4, 2016 for lead abuse-deterrent candidate ARYMO™ ER (morphine sulfate) extended-release tablets .FDA prescription drug user fee act (pdufa) goal date for a decision is October 14, 2016.  Full Article

BRIEF-Broadfin Capital Reports 9.99 Pct Passive Stake In Egalet Corp

* BROADFIN CAPITAL LLC REPORTS A 9.99 PCT PASSIVE STAKE IN EGALET CORP AS OF DEC 27, 2017 - SEC FILING Source text: (http://bit.ly/2lRMZcH) Further company coverage: